Q2 Earnings Estimate for IDYA Issued By Wedbush

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Research analysts at Wedbush issued their Q2 2025 earnings per share (EPS) estimates for shares of IDEAYA Biosciences in a report released on Tuesday, May 6th. Wedbush analyst R. Driscoll forecasts that the company will earn ($0.88) per share for the quarter. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($3.07) per share. Wedbush also issued estimates for IDEAYA Biosciences’ Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($1.02) EPS, FY2025 earnings at ($3.69) EPS, FY2026 earnings at ($4.08) EPS, FY2027 earnings at ($3.82) EPS, FY2028 earnings at ($2.31) EPS and FY2029 earnings at $0.53 EPS.

Several other research firms have also issued reports on IDYA. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Stephens restated an “overweight” rating and set a $50.00 target price on shares of IDEAYA Biosciences in a report on Friday, February 14th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $61.00 price target on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, IDEAYA Biosciences presently has an average rating of “Moderate Buy” and an average price target of $53.58.

IDEAYA Biosciences Stock Performance

IDYA stock opened at $17.37 on Friday. The firm has a market cap of $1.52 billion, a P/E ratio of -5.26 and a beta of 0.26. The firm’s fifty day moving average is $17.74 and its 200 day moving average is $22.64. IDEAYA Biosciences has a 52 week low of $13.45 and a 52 week high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.07). During the same quarter last year, the company posted ($0.53) EPS.

Institutional Trading of IDEAYA Biosciences

Several large investors have recently added to or reduced their stakes in the stock. R Squared Ltd purchased a new stake in shares of IDEAYA Biosciences in the 4th quarter worth about $35,000. CWM LLC raised its stake in IDEAYA Biosciences by 325.7% in the first quarter. CWM LLC now owns 2,371 shares of the company’s stock worth $39,000 after buying an additional 1,814 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in IDEAYA Biosciences by 180.2% in the first quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company’s stock worth $39,000 after buying an additional 1,546 shares during the period. GF Fund Management CO. LTD. bought a new stake in IDEAYA Biosciences during the 4th quarter valued at approximately $47,000. Finally, Signaturefd LLC grew its holdings in shares of IDEAYA Biosciences by 374.8% during the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company’s stock worth $47,000 after acquiring an additional 2,271 shares during the period. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.